CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy

• Published in: Theranostics Vol. 12; no. 16; pp. 6915 - 6930
• Main Authors: Khan, Tashbib, Lyons, Nicholas J, Gough, Madeline, Kwah, Kayden K X, Cuda, Tahleesa J, Snell, Cameron E, Tse, Brian W, Sokolowski, Kamil A, Pearce, Lesley A, Adams, Timothy E, Rose, Stephen E, Puttick, Simon, Pajic, Marina, Adams, Mark N, He, Yaowu, Hooper, John D, Kryza, Thomas
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01.01.2022; Ivyspring International Publisher
• Subjects: Animals; Antigens, Neoplasm; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Binding sites; Cancer therapies; Cell Adhesion Molecules; Cell Line, Tumor; Colorectal cancer; Colorectal Neoplasms; Cytotoxicity; Cytotoxins; Experiments; Female; Flow cytometry; Humans; Immunoconjugates - pharmacology; Ligands; Male; Mice; Microscopy; Monoclonal antibodies; Ovarian cancer; Patients; Payloads; Prostate cancer; Research Paper; RNA, Messenger; Tumors; Xenograft Model Antitumor Assays; Zirconium; theranostics; cancer; CDCP1; antibody-drug conjugate; receptor

An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are currently used clinically as anti-cancer agents significantly improving patient survival. Herein, we evaluated...